Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALZ002 DS (Rosolutamide) in Healthy Volunteers
NCT04392830Phase 1Completed
- Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in spinal and bulbar muscular atrophy (SBMA) comparing ALZ002 DS with Placebo (2 arms). Primary endpoint: Incidence of SAEs and treatment-related adverse events. Started May 2020; status: completed.
02
Drugs
rosolutamide
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on NCT04392830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392830.